CYP1A2 inhibitors eg theophylline + Analgrelide-
anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present for
interaction with other coadministered medications sharing the same clearance mechanism
Sucrafate + Analgrelide -
a single report suggest that sucralfate may interfere with analgrelide absorption
Analgrelide + Aspirin-
anagrelide enhanced the inhibition of platelet aggregation with aspirin
Analgrelide + cyclic AMP PDE III eg milirone, enoximone, amiranone, olprinone, clilostazol-
anagrelide is an inhibitor of cyclic AMP PDE III. The effects of medicinal products with similar
properties may be exacerbated by analgrelide
Cardiovascular- use anagrelide with caution in patients with known or suspected heart disease,
and only if the potential benefit outweigh the potential risk.
Therapeutic doses of analgrelide may cause cardiovascular effects including vasodilation,
tachycardia, palpitations, and congestive heart failure.
Cesstion of treatment- after sudden stoppage of analgrelide therapy, the increase in platelet
count can be observed within 4 days.
Hepatic function impairment- assess the potential risks and benefits in a patient with mild to
moderate hepatic impairment, before treatment begins. In such patients dose reduction is
required. Carefully monitor patients with cardiovascular effects.
Pregnancy- instruct patients of child bearing age that they should use contraception while taking
analgrelide. Anagrelide may cause fetal harm when administered to a pregnant women.
Lactation- decide whether to discontinue breast feeding or the drug depending on the importance
of the drug to the mother
Children- no overall difference in dosing and safety were observed between pediatric and adult
Monitoring- monitor platelet count, blood counts, hemoglobin, blood counts, white cells counts,
liver function tests AST, ALT and renal function ( serum creatinine, serum urea nitrogen BUN.
Platelet counts should be performed every 2 days, during the first week of treatment and at least
weekly, thereafter until the maintenance dosing is reached
Dosages/ Overdosage Etc:
Dosage- Recommended starting dose- for adults- 0.5mg 4 times daily or 1mg 2 times daily, which should be
maintained for at least 1 week.
Starting dose in pediatric patients have ranged from 0.5mg/day to 0.5mg 4 times daily
An initial starting dose of 0.5mg/day is recommended
The mechanism by which analgrelide reduces blood platelet count is still under investigation. Studies
support a hypothesis of dose related reduction in the platelet reduction resulting from a decrease in
Pregnancy and lactation:
Instruct patients of child bearing age that they should use contraception while taking
anagrelide. Anagrelide may cause fetal harm when administered to a pregnant women.
Decide whether to discontinue breast feeding or the drug depending on the importance
of the druug to the mother
No overall difference in dosing and safety were observed between pediatric and adult
Disclaimer: Every effort has been made to ensure that the information provided in
this Database is authentic and accurate. Commissions or omissions in the database,
if any, are purely inadvertent and the site owner shall not accept any liability
whatsoever for any adverse consequences of any nature arising to any individual
or third party, as a result of usage of this information.